Discussion assesses cost effectiveness of prophylactic mastectomy and reconstruction in BRCA1/2-positive patients, indicating potential benefits.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Rochlin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: